ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0647

Adherence to Hydroxychloroquine Dosing and Teleretinal Screening: Assessment and Quality Improvement

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0653

Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0789

Adipokine Levels and Associations with Achievement of Low Disease Activity in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

8:30AM-10:30AM: Abstract Number: 0685

Adipokines and Loss of Lean Mass Among Patients with Rheumatoid Arthritis

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0897

Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)

8:30AM-10:30AM: Abstract Number: 0569

All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Abstract Number: 0582

Altered Risk of Gout According to Change of Metabolic Parameters in Young Adults

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Abstract Number: 0825

An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0731

An Open-Label Study to Evaluate the Effect of Intra-articular Triamcinolone Acetonide Extended Release on Patients with Baseline Synovitis and Osteoarthritis of the Knee

Osteoarthritis – Clinical Poster II (0723–0738)

8:30AM-10:30AM: Abstract Number: 0816

Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0879

Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular Risk Impairing the Immune and Cardiovascular Systems

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0704

Anti-SSa/SSb and Ro52 and Interstitial Lung Disease in Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0696

Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0876

Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0652

Application of a GCA Probability Score to Patients Referred to a GCA Fast Track Clinic

Measures & Measurement of Healthcare Quality Poster (0623–0659)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].